Table 4. Multivariate Cox Hazard Proportional Analyses of Overall Survival of All Patients.
Variable | GRIm-score |
RMH score |
||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Age (years) | ||||
< 75 | 1 (Reference) | 1 (Reference) | ||
≥ 75 | 1.34 (0.87 - 2.06) | 0.19 | 1.29 (0.82 - 2.02) | 0.27 |
BMI | ||||
≥ 18.5 | 1 (Reference) | 1 (Reference) | ||
< 18.5 | 1.39 (0.79 - 2.45) | 0.25 | 1.57 (0.89 - 2.77) | 0.12 |
Platinum-based | ||||
Cisplatin | 1 (Reference) | 1 (Reference) | ||
Carboplatin | 0.94 (0.54 - 1.62) | 0.82 | 0.82 (0.48 - 1.41) | 0.48 |
ECOG-PS | ||||
0 - 1 | 1 (Reference) | 1 (Reference) | ||
2 - 4 | 2.16 (1.41 - 3.31) | < 0.01 | 2.12 (1.38 - 3.24) | < 0.01 |
No. of metastases | ||||
< 3 | 1 (Reference) | |||
≥ 3 | 1.97 (1.29 - 3.02) | < 0.01 | ||
GRIm-score | ||||
Low (0 - 1) | 1 (Reference) | |||
High (2 - 3) | 1.80 (1.20 - 2.72) | < 0.01 | ||
NLR | ||||
< 6 | 1 (Reference) | |||
≥ 6 | 1.17 (0.65 - 2.09) | 0.60 | ||
RMH score | ||||
Low (0 - 1) | 1 (Reference) | |||
High (2 - 3) | 1.93 (1.27 - 2.92) | < 0.01 |
BMI: body mass index; CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group performance status; GRIm-score: Gustave Roussy immune score; HR: hazard ratio; NLR: neutrophil-to-lymphocyte ratio; RMH score: Royal Marsden Hospital prognostic score.